Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1

Neoplasia

Volumn 13, Issue 9, 2011, Pages 854-863

  Lu, Huarui ^a,b   Liu, Ping ^a,b   Pan, Yunqian ^a,b,c   Huang, Haojie ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; FO1 6NLS PEPTIDE; PEPTIDE DERIVATIVE; SERINE; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; CYTOPLASM; ENZYME BINDING; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 80053454440     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11594     Document Type: Article

References (44)

1. Huang H and Tindall DJ (2007). Dynamic FoxO transcription factors. J Cell Sci 120, 2479-2487.
2. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, and GreenbergME (1999). Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857-868.
3. Modur V, Nagarajan R, Evers BM, and Milbrandt J (2002). FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277, 47928-47937.
4. Dijkers PF, Medema RH, Lammers JW, Koenderman L, and Coffer PJ (2000). Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10, 1201-1204.
5. Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM, and Medema RH (2002). The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168, 5024-5031.
6. Gilley J, Coffer PJ, and Ham J (2003). FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162, 613-622.
7. Medema RH, Kops GJ, Bos JL, and Burgering BM (2000). AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27Kip1. Nature 404, 782-787.
8. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, and Sellers WR (2000). Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20, 8969-8982.
9. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, and Sellers WR (2002). A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2, 81-91.
10. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM, and Medema RH (2002). Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22, 7842-7852.
11. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, DiStefano PS, Chiang LW, and Greenberg ME (2002). DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296, 530-544.
12. Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, and Motoyama N (2002). FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. J Biol Chem 277, 26729-26732.
13. Nemoto S and Finkel T (2002). Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295, 2450-2452.
14. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, and Burgering BM (2002). Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419, 316-321.
15. Li P, Lee H, Guo S, Unterman TG, Jenster G, and Bai W (2003). AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 23, 104-118.
16. Huang H, Muddiman DC, and Tindall DJ (2004). Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem 279, 13866-13877.
17. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, and Tindall DJ (2005). Skp2 inhibits FOXO1 in tumor suppression through ubiquitinmediated degradation. Proc Natl Acad Sci USA 102, 1649-1654.
18. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
19. Li DM and Sun H (1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57, 2124-2129.
20. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15, 356-362.
21. Maehama T and Dixon JE (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273, 13375-13378.
22. Tang ED, Nunez G, Barr FG, and Guan KL (1999). Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274, 16741-16746.
23. Biggs WH III, Meisenhelder J, Hunter T, Cavenee WK, and Arden KC (1999). Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96, 7421-7426.
24. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, and Burgering BM (1999). Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 398, 630-634.
25. Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX, Chung LW, Zhou W, and Dong JT (2006). FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 66, 6998-7006.
26. Huang H, Regan KM, Lou Z, Chen J, and Tindall DJ (2006). CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314, 294-297.
27. Liu P, Kao TP, and Huang H (2008). CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene 27, 4733-4744.
28. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, and Tindall DJ (2001). PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 276, 38830-38836.
29. Zhao X, Gan L, Pan H, Kan D, Majeski M, Adam SA, and Unterman TG (2004). Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. Biochem J 378, 839-849.
30. Liu P, Li S, Gan L, Kao TP, and Huang H (2008). A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res 68, 10290-10299.
31. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, and Narayan P (1995). Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 31, 14-24.
32. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, et al. (2007). FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128, 309-323.
33. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, and Kaelin WG (1996). Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 16, 6623-6633.
34. Mendoza N, Fong S, Marsters J, Koeppen H, Schwall R, and Wickramasinghe D (2003). Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res 63, 1020-1024.
35. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, et al. (1998). Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90, 1284-1291.
36. Freedland SJ, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, and Aronson WJ (2003). Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 169, 1325-1330.
37. Toyoshima H and Hunter T (1994). P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78, 67-74.
38. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, and Nakayama KI (2004). Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 6, 661-672.
39. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, and Dutta A (1996). Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 56, 4159-4163.
40. Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP, and Ross JS (1997). The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 80, 753-763.
41. Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Muraca PJ, and Ross JS (1998). Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 16, 1302-1309.
42. Ozen M and Ittmann M (2005). Increased expression and activity of Cdc25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res 11, 4701-4706.
43. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, et al. (2003). Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72, 270-280.
44. Wu X, Dong X, Liu W, and Chen J (2006). Characterization of CHEK2 mutations in prostate cancer. Hum Mutat 27, 742-747.